These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24926885)

  • 1. Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency.
    Ohnishi Y; Minamino Y; Kakudo K; Nozaki M
    Oncol Rep; 2014 Aug; 32(2):780-6. PubMed ID: 24926885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway.
    Ohnishi Y; Yasui H; Kakudo K; Nozaki M
    Int J Oncol; 2015 Dec; 47(6):2165-72. PubMed ID: 26497980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway.
    Ohnishi Y; Yasui H; Kakudo K; Nozaki M
    Oncol Rep; 2016 Nov; 36(5):3058-3064. PubMed ID: 27633099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
    Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells.
    Takaoka S; Iwase M; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M; Shintani S
    Int J Oncol; 2007 Jun; 30(6):1469-76. PubMed ID: 17487368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Migration of oral squamous cell carcinoma cells are induced by HGF/c-Met signalling via lamellipodia and filopodia formation.
    Yasui H; Ohnishi Y; Nakajima M; Nozaki M
    Oncol Rep; 2017 Jun; 37(6):3674-3680. PubMed ID: 28440510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells.
    Iwase M; Takaoka S; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M
    Oral Oncol; 2008 Apr; 44(4):361-8. PubMed ID: 17689285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR codon 497 polymorphism - implications for receptor sensitivity to inhibitors in HNSCC cell lines.
    Krohn V; Wiegand S; Werner JA; Mandic R
    Anticancer Res; 2011 Jan; 31(1):59-65. PubMed ID: 21273581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.
    Yin P; Cui S; Liao X; Yao X
    Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel in combination with cetuximab exerts antitumor effect by suppressing NF-κB activity in human oral squamous cell carcinoma cell lines.
    Harada K; Ferdous T; Kobayashi H; Ueyama Y
    Int J Oncol; 2014 Dec; 45(6):2439-45. PubMed ID: 25230791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.
    Kitahara H; Hirai M; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
    Oncol Rep; 2016 Dec; 36(6):3139-3144. PubMed ID: 27779690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
    Jedlinski A; Ansell A; Johansson AC; Roberg K
    J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
    Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells.
    Saki M; Toulany M; Rodemann HP
    Radiother Oncol; 2013 Sep; 108(3):473-8. PubMed ID: 23891090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
    Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
    Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
    Troiani T; Martinelli E; Napolitano S; Vitagliano D; Ciuffreda LP; Costantino S; Morgillo F; Capasso A; Sforza V; Nappi A; De Palma R; D'Aiuto E; Berrino L; Bianco R; Ciardiello F
    Clin Cancer Res; 2013 Dec; 19(24):6751-65. PubMed ID: 24122793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
    Chang CM; Chang PY; Tu MG; Lu CC; Kuo SC; Amagaya S; Lee CY; Jao HY; Chen MY; Yang JS
    Oncol Rep; 2012 Nov; 28(5):1799-807. PubMed ID: 22923287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.
    Amaro A; Mirisola V; Angelini G; Musso A; Tosetti F; Esposito AI; Perri P; Lanza F; Nasciuti F; Mosci C; Puzone R; Salvi S; Truini M; Poggi A; Pfeffer U
    Eur J Cancer; 2013 Oct; 49(15):3353-65. PubMed ID: 23849826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.